A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy: Designing an Advanced Category rFVIII Concentrate

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 2, Issue , 2008, Pages 419-449

  Riedel, Norbert ^a   Dorner, Friedrich ^b  

^a Baxter International Inc   (United States)

^b BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Biosynthesis; Calreticulin; Efficacy; Hemophilia; Pathogen

Indexed keywords

EID: 84885540505     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch18     Document Type: Chapter

References (32)

1. B. Arun, C.M. Kessler, Clinical manifestations and therapy of the hemophilias. In: Colman R.W., Clowes A.W., Hirsh J, George J. N., Marder V. J., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th edn. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2000:815-824.
2. G. C. White II, F. Rosendaal, L.M. Aledort, J.M. Lusher, C. Rothschild, J. Ingerslev, for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Thromb Hemost 2001;85:560.
3. M.W. Hilgartner. Current treatment of hemophilic arthropathy. Curr Opin Pediatr. 2002;14:46-49.
4. US Department of Health and Human Services. Report on the Universal Data Collection Program (UDC). Atlanta, GA: Hematologic Diseases Branch, Centers for Disease Control and Prevention; 2002:4.
5. M.W. Hilgartner. The need for recombinant factor VIII: historical background and rationale. Semin Hematol 1991;28(suppl 1):6-9.
6. P.M. Mannucci, E.G. Tuddenham. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001;344:1773-1779.
7. W. K. Hoots. History of plasma-product safety. Transfus Med Rev 2001;15(suppl 1):3-10.
8. Data on file, Baxter Healthcare Corporation.
9. G. C. White II, S. Courter, G.L. Bray, M. Lee, E. Gomperts, and the Recombinate Previously Treated Patient Study Group. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A. Thromb Hemost 1997;77:660-667.
10. G. L. Bray, E. Gomperts, S. Carter, et al., for the Recombinate Study Group. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated subjects with hemophilia A. Blood 1994;83:2428-2435.
11. R. Gruppo, G. L. Bray, P. Schroth, et al. Safety and immunogenicity of recombinant factor VIII (RecombinateTM) in previously untreated subjects (PUPs): a 6.5 year update. Thromb Hemost 1997; (suppl):162. Abstract PD-663.
12. A. Mitterer, W. Mundt, F. Dorner, E. Bjornson. Development of an advanced category recombinant Factor VIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PRM). Poster presented at ISTH, Birmingham, July 12-18, 2003.
13. P. Brown. Transfusion medicine and spongiform encephalopathy. Transfusion 2001;41:433-436.
14. P. Brown. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. Br Med J 2001;322:841-844.
15. United Kingdom Hemophilia Centre Doctors' Organisation (UKHCDO). Guidelines on the selection and use of therapeutic products to treat hemophilia and other hereditary bleeding disorders. Hemophilia 2003;9:1-23.
16. National Hemophilia Foundation. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders. MASAC Recommendations. Revised November 2002; No. 135.
17. P. J. Lenting, J. A. van Mourik, K. Mertens. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998;92:3983-3996.
18. R. J. Kaufman, S. E. Antonarakis, P. J. Fay. Factor VIII and hemophilia A. In: Colman R.W., Clowes A.W., Hirsh J., George J. N., Marder V. J., eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th edn. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000:135-156.
19. R. A. Gruppo, D. Brown, M.M. Wiles, R. J. Navickis. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis-a meta-analysis. Hemophilia 2003;9:251-260.
20. ReFacto® Antihemophilic factor (Recombinant) Prescribing Information. Wyeth Pharmaceuticals.
21. B. Zhang, M.A. Cunningham, W. C. Nichols, et al. Bleeding due to disruption of a cargospecific ER-to-Golgi transport complex. Nat. Genet. 2003;34(2):220-225.
22. R. J. Kaufman, S.W. Pipe. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Hemost 1999;82(2):201-208.
23. R. J. Kaufman, L. C. Wasley, M.V. Davies, R. J. Wise, D.I. Israel, A. J. Dorner. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989;9(3):1233-1242.
24. E. Gomperts, R. Lundblad, R. Adamson. The manufacturing process of recombinant factor VIII, Recombinate. Transfus Med Rev 1992;6:247-251.
25. M. Tarantino, I. Lopez, L. Navale, G. L. Bray. Pharmacokinetic evaluation of a new proteinfree manufactured recombinant FVIII, rAHFPFM. Poster presented at WFH, Seville, 2002.
26. rAHF-PFM European Public Assessment Report (EPAR) scientific discussion; http:// www.emea.eu.int/index/indexh1.htm.
27. A. Shapiro, M. Tarantino, I. Warrier, et al. Ongoing Evaluation of an Advanced Category Recombinant FVIII Processed Using a Plasma/ Albumin-Free Method, rAHF-PFM. Poster presented at National Hemophilia Foundation, Salt Lake City, November 6-8, 2003.
28. M.D. Tarantino, L.M. Navale, G.L. Bray, B.M. Ewenstein. Clinical evaluation of a new generation recombinant FVIII, plasma/albumin free method (rAHF-PFM). Blood 2002;100(suppl):493.
29. M.D. Tarantino, L. Navale, G. Bray, B. Ewenstein. Clinical evaluation of a new generation recombinant FVIII, plasma/albumin-free method (rAHF-PFM), in previously treated patients. Poster presented at: Annual Meeting of the American Society of Hemophilia; December 6-10, 2002; Philadelphia, PA.
30. J. Astermark, C. Negrier, P. Schroth et al. Clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in surgical settings. Poster presented at ISTH, Birmingham, July 12-18, 2003.
31. C. Negrier, J. Astermark, I. Pabinger, J. Di Paola et al. Surgical Evaluation of rAHF-PFM, an Advanced Category Recombinant Antihemophilic Factor Prepared Using a Plasma/Albumin-Free Method. Blood 2003;102(11):Abstract 2944.
32. K. Hoots, V. Blanchette, A. Shapiro, L. Navale et al. Clinical evaluation of an advanced category recombinant FVIII, antihemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients. Poster presented at ISTH, Birmingham, July 12-18, 2003.